

Review

Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease

Portal hypertension is the major complication of chronic liver disease and is associated with reduced survival.¹ Pharmacological treatment is based on the premise that a sustained reduction in portal pressure will reduce the consequences of portal hypertension—that is, variceal bleeding, hepatic encephalopathy, and development of ascites.²

Non-selective β -blockers have proved effective in reducing portal pressure by lowering splanchnic blood inflow³ and are used in primary and secondary prevention of variceal bleeding.^{4–5} However, the mean decrease in portal pressure in response to propranolol is only approximately 15%⁶ and one third of cirrhotic patients do not respond despite adequate blockade.⁷

During the last decade, increased knowledge of the pathophysiology of portal hypertension has resulted in the use of new pharmacological targets; most importantly for the reduction of intrahepatic resistance, which is now recognised to be due in part to activated stellate cell contraction (myofibroblasts). These represent mesenchymal cells that reside in the perisinusoidal space of Disse and resemble tissue pericytes, a cell type with smooth muscle features that is thought to regulate blood flow via pericapillary constriction.⁸ During liver injury they undergo “activation”, characterised by production of increased amounts of extracellular matrix and are responsible for fibrosis.⁹ Moreover, experimental data provide strong evidence that activated stellate cells are contractile and may regulate sinusoidal blood flow, especially in the injured liver.¹⁰

The renin-angiotensin-aldosterone system (RAAS) is usually activated in patients with liver cirrhosis and this represents a homeostatic response to counterbalance the vasodilatation, arterial hypotension, and renal hypoperfusion observed in portal hypertension.¹¹ Plasma renin activity (PRA) is elevated in cirrhotics and is correlated with the hepatic venous pressure gradient (HVPG).¹² Angiotensin II (ANG-II) is considered a potential mediator of intrahepatic portal hypertension because its plasma levels are elevated in cirrhosis,¹³ and infusion of ANG-II induces a rise in portal pressure.¹⁴ Enhancement of the adrenergic vasoconstrictor influence on the portal system,¹⁵ direct contractile influence on activated stellate cells,¹⁶ and sodium and fluid retention induced by stimulation of aldosterone secretion¹⁷ are possible mechanisms that contribute to the portal hypertensive effect of ANG-II.

Hence, in theory, blockade of the RAAS by angiotensin converting enzyme (ACE) inhibitors/ANG-II receptor antagonists should be beneficial for improvement of fluid and salt secretion and reduce portal pressure in cirrhotic patients. ACE inhibitors block the RAAS preventing the conversion of inactive angiotensin I to active ANG-II,¹⁸ and may improve portal hypertension. However, concerns have been raised about their safety because of arterial hypotension and deterioration of renal function.

Orally active ANG-II receptor antagonists represent the most recent therapeutic development in the inhibition of RAAS.¹⁹ They are effective and safe in the control of systemic hypertension acting through specific AT1 receptors. Recently, the ANG-II receptor antagonists losartan

and irbesartan have been studied in portal hypertensive patients with promising results.^{20–21}

We review the therapeutic effects of these drugs in cirrhotic patients.

Effects on renal function

SINGLE DOSE STUDIES (TABLE 1)

There are four studies involving 63 cirrhotics using ACE inhibitors.^{22–25} Captopril was used in 55 patients at doses ranging from 12.5 to 150 mg. In the first three studies captopril caused a significant reduction in glomerular filtration rate (GFR) with a consequent decrease in urinary volume and urinary sodium excretion, in association with significant decreases in mean arterial pressure (MAP).^{22–24} In the only randomised placebo controlled study, by Gentilini and colleagues,²⁵ patients who had arterial hypotension after a single intravenous dose of captopril were excluded from the analysis so as to elucidate if the deleterious renal effects in the previous studies were secondary to arterial hypotension. However, captopril still induced a significant decrease in GFR and urinary sodium excretion in patients with or without ascites. Therefore, ANG-II contributes to the maintenance of renal haemodynamics in cirrhosis and consequently ACE inhibitors are harmful.

A subsequent study of 10 mg of enalapril in eight cirrhotic patients²² showed increased hourly urine volume and renal sodium excretion during the first two hours, but 24 hour urinary volume was unchanged.

Recently, Girgrah and colleagues²⁶ evaluated the role of ANG-II in sodium homeostasis in nine preascitic cirrhotic patients using losartan, its receptor antagonist. A dose-response study showed that 7.5 mg was the optimal dose to produce natriuresis without systemic hypotension, normalising renal sodium without changes in systemic or renal haemodynamics. In the absence of GFR or renal plasma flow (RPF) changes, one would speculate that ANG-II has a direct sodium retaining effect on the renal tubule. However, baseline systemic ANG-II levels were significantly lower in preascitic cirrhotics compared with controls. The authors suggested that intrarenal production of ANG-II or increased sensitivity of preascitic cirrhotics to the sodium retaining effect of ANG-II would explain this discrepancy. Alternatively, losartan could have reduced portal pressure and thus improved sodium retention, without a direct effect on renal haemodynamics.

MULTIPLE DOSE STUDIES (TABLE 2)

In 1983, Saruta and colleagues²⁷ used the ACE inhibitor SQ14225 in six cirrhotics for seven days. ANG-II and plasma aldosterone levels decreased and PRA increased markedly. Although systemic blood pressure was lowered, urinary sodium excretion increased significantly in five of

Abbreviations used in this paper: ANG-II, angiotensin II; ACE, angiotensin converting enzyme; GFR, glomerular filtration rate; HSCs, hepatic stellate cells; HVPG, hepatic venous pressure gradient; MAP, mean arterial pressure; PRA, plasma renin activity; RAAS, renin-angiotensin-aldosterone system; RPF, renal plasma flow; WHVG, wedged hepatic venous gradient.

Table 1 Single dose studies of the effects of angiotensin converting enzyme inhibitors/angiotensin II receptor antagonists on renal function, urine output, and sodium excretion

Author/year	No patients	Ascites	Drug dose (mg)	Urinary Na output	Creatinine clearance or GFR (ml/min)	Urine volume	MAP (mm Hg)
Girgah, 2000 ²⁶	9	No	Losartan 7.5 orally	154 (8) to 202 (12) mmol/day*	90 (9) to 92 (11)	NA	88 (3) to 84 (4)
Pariente, 1985 ²³	6	Yes	Captopril 25 orally	In 4 remained <5 µmol/min. In 2, drop from 198 and 200 to <5 µmol/min	9.3 (23) to 71 (2.4)*	1.9 (0.4) to 1 (0.4) ml/min*	87 (10.6) to 72.5 (7.3)*
Daskalopoulos, 1987 ²⁴	11	Yes	Captopril 50–150 orally	2.7 (1) to 0.48 (0.21) mmol/h*	Inulin clearance 73 (8) to 76 (7)	377 (55) to 182 (42) ml/h*	88 (1) to 74 (1)*
Ohnishi, 1990 ²²	8	Yes	Captopril 50 orally	114.8 (12.2) to 85.6 (10.2) mmol/day	NA	1800 (170.6) to 1422 (143.2) ml/day	90.5 to 76*
	8	Yes	Enalapril 10 orally	103.2 (12.1) to 113.7 (32.7) mmol/day†	NA	1940 (168.3) to 2192.5 (226.9) ml/day†	92.7 to 82*
Gentilini, 1993 ²⁵	30	Yes (n=9)	Captopril 12.5 intravenous	43.8 (placebo) v 30.6 (drug) µmol/min*	108 (7) (placebo) v 78 (9) (drug)*	2.7 (0.7) (placebo) to 2.1 (0.4) (drug) ml/min	Reduction <5
		No (n=21)	Captopril 12.5 intravenous	40.3 (6.1) (placebo) v 29.3 (7.6) (drug) µmol/min*	102 (4) (placebo) v 88 (3) (drug)*	3.9 (0.3) (placebo) to 4.2 (0.3) (drug) ml/min	Reduction <5

Values are mean (SD).

NA, data not given in the studies or not applicable; GFR, glomerular filtration rate; MAP, mean arterial pressure.

*Statistically significant compared with baseline; †statistically significant compared with captopril.

six patients, and ascites improved but did not disappear. Since then, five studies^{28–32} comprising 60 patients with ascites have been reported using captopril (9–75 mg/day) given for 3–21 days. In three studies,^{28–30} captopril caused a significant reduction in body weight, enhancement of urinary sodium excretion, and improvement of fluid balance in the majority of patients. However, Wood and colleagues³¹ used captopril for three days in four patients with resistant ascites and reported falls in MAP with subsequent falls in GFR, decreases in sodium excretion, and no improvement in ascites. These authors suggested that ACE inhibitors have little place in the treatment of patients with resistant ascites and may be harmful. The only randomised placebo controlled study was performed by Tsai and

colleagues³² and included 50 patients with ascites. PRA became significantly raised in the captopril group, and this was considered as adequate blockade of ACE. Nevertheless, there was no significant change in urine volume, creatinine clearance, or RPF, and the improvement in urine sodium excretion was not significant.

Enalapril was used in two small studies^{33, 34} with 18 patients. In one,³³ a significant increase in urinary volume and sodium excretion was seen. In both studies creatinine clearance improved significantly.

Evaluation of the above studies is difficult because most were neither placebo controlled nor randomised. Furthermore, as patient characteristics differed considerably between studies (for example, Child-Pugh class, presence

Table 2 Multiple dose studies of the effects of angiotensin converting enzyme inhibitors on renal function, urine output, and sodium excretion†

Author/year	No patients	Drug dose (mg/day)	Duration (day)	Urinary Na output (mmol/day)	Creatinine clearance or GFR (ml/min)	Urine volume (ml/day)	MAP (mm Hg)
Saruta, 1983 ²⁷	6	SQ14225 75 mg	7	100 (5) to 165 (16) in 5 of 6*	Unchanged	1400 (210) to 1800 (180)*	92.6 (7) to 87 (7)
Brunkorst, 1989 ²⁸	14	Captopril 12.5 mg for 5 days then 25 mg for 5 days	10	70 to 125*	53.7 (7.8) to 66.9 (15.1)	Fluid balance: +200 to –600*	84 (2.9) to 78.4 (2.9)
Ibarra, 1992 ²⁹	9	Captopril 75 mg	21	36.7 (9.5) to 103 (13.8) 7 of 9 patients*	NA	NA	86.9 (2.6) to 80.2 (3.7)
Van Vliet, 1992 ³⁰	8	Captopril from 9 to 37.5 mg	20	72.8 (35.2) to 1128.5 (63.5) in 4 responders*	NA	1207 (456) to 1646 (395) in 4 responders*	79.8 (7.3) to 72.6 (9) in 4 responders
				40.9 (35) to 42.4 (32) in 4 non-responders		1107 (334) to 1375 (424) in 4 non-responders	86.3 (5.9) to 84.2 (9.4) in 4 non-responders
Wood, 1985 ³¹	4	Captopril from 18.75 to 37.5 mg	3	14.25 to 6.5‡	70 to 46‡	NA	87 to 78‡
Tsai, 1996 ³²	25	Captopril 6.25 tds	14	20 (5) to 26 (6)	45 (11) to 40 (10)	790 (111) to 725 (85)	88 (3) to 86 (4)
	25	Placebo	14	21 (6) to 18 (4)	41 (10) to 38 (11)	653 (78) to 750 (97)	86 (2) to 85 (3)
Ohnishi, 1994 ³³	10	Enalapril 10 mg	8	73 to 110‡*	47 to 60‡*	1800 to 2300‡*	NA
Amarapurkar, 1994 ³⁴	8	Enalapril 10 mg	7	NA	46.5 (15.4) to 73.2 (19.7)*	NA	NA

Values are mean (SD).

NA, data not given or not applicable; GFR, glomerular filtration rate; MAP, mean arterial pressure.

‡Numbers obtained by measurement and/or calculation on figures.

*Statistically significant.

†All patients had ascites.

Table 3 Studies of the effects of angiotensin converting enzyme inhibitors on portal pressure

Author/year	No patients	Drug dose (mg)	Duration	WHVP (mm Hg)	FHVP (mm Hg)	HVPG (mm Hg)	MAP (mm Hg)
Eriksson, 1984 ⁴⁰	7	Captopril 12.5–25 mg	Single oral	22 (2) to 19 (2)	8 to 5‡	14 (2) to 13 (2)	93 (3) to 79 (7)*
Pariente, 1985 ²³	6	Captopril 12.5 mg	Single oral	NA	NA	19.7 (3.6) to 18.8 (3.7)	87 (10.6) to 72.5 (7.3)*
Ibarra, 1992 ²⁹	9	Captopril 25 mg	Single oral	22.9 (2.7) to 20.7 (2.4)	15 (1.8) to 12.1 (0.9)	7.58 (1.5) to 8.58 (2)	86.9 (2.6) to 77 (1.9)*
Tsai, 1996 ³²	25	Captopril 18.75 mg	2 weeks	NA	NA	17.2 (1.3) to 17.5 (1.2)	88.3 (3) to 86 (4)
	25	Placebo	2 weeks	NA	NA	17.6 (1.1) to 17.8 (1.1)	86 (2) to 85 (3)
Ibarra, 1992 ²⁹	9	Captopril 75 mg	3 weeks	22.9 (2.7) to 18.8 (2.9)	15 (1.8) to 9.4 (0.5)	7.6 (1.5) to 9.3 (2.7)	86.9 (2.6) to 80.2 (3.7)
Svoboda, 1992 ⁴²	12	Enalapril 20 mg	12 weeks	25.5 (4.8) to 21.3 (4.8)*	8.0 (2.8) to 8.6 (2.3)	17 (6) to 12.6 (3.4)*	14.1 (4.1) to 12.5 (3.8)
	13	Placebo	12 weeks	22.8 (7.1) to 23.3 (6.7)	8.7 (4.3) to 8.2 (3.8)	14.2 (5.1) to 15.2 (3.4)	13.6 (4) to 12.8 (4.2)
Chiang, 1995 ⁴¹	20	Enalaprilat 2.5 mg	Single intravenous	32.1 (5.1) to 25.6 (7.2)*	11.2 (3.7) to 10.7 (3.7)*	21 (4.3) to 16.1 (4.5)*	94.1 (11.2) to 85.6(13.8)*

Values are mean (SD).

NA, data not available; WHVP, wedged hepatic venous pressure; FHVP, free hepatic venous pressure; HVPG, hepatic venous pressure gradient; MAP, mean arterial pressure.

*Statistically significant.

‡Numbers obtained by measurement and/or calculation on figures.

of ascites, salt restriction, use of diuretics, and renal function impairment) it is difficult to make comparisons.

Single doses of captopril worsen renal function^{22–25} but this reflects only the immediate haemodynamic effects, which may not be the case with long term treatment. Indeed, some neurohormonal changes (for example, decrease in aldosterone levels) are evident only after long term treatment, as highlighted by Ohnishi and colleagues.³³ There are five multiple dose studies showing that captopril and enalapril enhance renal sodium excretion.^{28–30 33 34} However, it is noteworthy that baseline urinary sodium excretion was more than 70 mmol/day in all of these studies compared with the very low baseline sodium excretion in the studies reporting no improvement.^{31 32} It is possible that only patients with an earlier stage of liver disease, and hence less renal impairment, may benefit from the use of ACE inhibitors.

However, in decompensated cirrhotics there is reduced peripheral resistance and a compensatory increase in plasma volume and cardiac output.³⁵ Under these conditions, activation of RAAS plays a critical role in maintaining arterial pressure and in autoregulation of GFR, which maintains GFR at near constant values despite a reduction in renal perfusion pressure.³⁶ Therefore, administration of ACE inhibitors or ANG-II antagonists in these patients would result in deterioration of renal function and worsening of sodium excretion.

Conversely, in patients with preascitic cirrhosis, in whom a subtle sodium handling abnormality is found, it is still not entirely clear if this is due to compensatory activation of the RAAS counteracting the consequences of hyperdynamic circulation³⁷ or if the RAAS plays a crucial pathogenetic role in abnormal sodium handling.³⁸ Girgrah and colleagues²⁶ emphasised the primary role of ANG-II in increased renal sodium reabsorption to explain the positive role of losartan in normalisation of sodium handling. Conversely, in the recent study by Helmy and colleagues³⁹ (despite the increase in plasma ANG-II concentrations in preascitic cirrhotics) there was still hyporesponsiveness of the peripheral vessels after administration of losartan. This supports the concept that ANG-II does not have a role in maintenance of vascular tone in these patients. Therefore,

use of ANG-II inhibitors could be beneficial in early cirrhosis to counteract the effects of raised ANG-II levels in renal sodium handling and would not have deleterious effects on systemic haemodynamics.

Effects on portal pressure

ACE INHIBITORS

Captopril has been evaluated in four studies (table 3).^{23 29 32 40} In three (22 patients), captopril was given as a single oral dose.^{23 29 40} No significant change in HVPG was detected in any study. In addition, there was a small but significant decrease in MAP with deterioration of systemic haemodynamics. Ibarra and colleagues²⁹ evaluated captopril after three weeks of administration, reporting a significant reduction in free hepatic venous pressure while wedged hepatic venous pressure (WHVP) decreased less. Therefore, HVPG was increased, although this was not significant. Finally, in the study of Tsai and colleagues,³² captopril given for 14 days had no effect on the systemic or hepatic circulation.

The efficacy of enalapril in the blockade of RAAS and therefore in reducing portal pressure was evaluated in two small studies (table 3). Chiang and colleagues⁴¹ used 2.5 mg of enalaprilat, the active metabolite of enalapril, by intravenous infusion, in 20 patients with cirrhosis associated with hepatitis B. HVPG was reduced significantly within 30 minutes in 13 of 20 patients. Although MAP fell, liver and renal function did not change significantly. Svoboda and colleagues⁴² reported a significant drop in HVPG after three months of administration of enalapril in 12 cirrhotics undergoing long term sclerotherapy; no reduction in HVPG was found in 13 controls who received placebo. Systemic haemodynamics and liver function did not change.

Only two of the above studies were randomised with the use of placebo^{32 42} but the small number of patients with different clinical characteristics makes it difficult to generalise. However, similar to the absence of renal effects, captopril failed to reduce portal pressure in all four studies.^{23 29 32 40} Interestingly, enalapril proved effective in two small studies (32 patients) although there was a poor response in patients with severe liver dysfunction (Child

Table 4 Studies of the effects of angiotensin II receptor antagonists on portal pressure

Author/year	No patients	Drug dose (mg)	Duration	WHVP (mm Hg)	FHVP (mm Hg)	HPVG (mm Hg)	MAP (mm Hg)
Arroyo, 1981 ⁴⁵	14	Saralasin 1–2.5 mg/kg/min	Single infusion	17.2 (0.9) to 13.7 (0.9)*	NA	NA	76.8 (4) to 61.1 (5.9)*
Schneider, 1999 ²⁰	30 (HVPG ≥20 mm Hg)	Losartan 25 mg	1 week	29.5 (3.8) to 18 (4.8)*	4.8 (2.2) to 4.8 (2.4)	24.8 (2.6) to 13.1 (4.1)*	89.1 (6.8) to 86 (7.8)*
	15 (HVPG ≥20 mm Hg)	Placebo	1 week	28.8 (3.3) to 27.9 (3.8)	4.9 (2.2) to 4.8 (2.1)	23.9 (4.1) to 23.1 (4.2)	88.3 (5.5) to 88.6 (4.5)
	15 (HVPG <20 mm Hg)	Losartan 25 mg	1 week	22.1 (2.6) to 14.1 (2.9)*	4.2 (1.6) to 4.1 (1.5)	17.9 (1.4) to 10 (2.7)*	90.9 (5.5) to 87.4 (4.6)*
	10 (HVPG <20 mm Hg)	Placebo	1 week	17.7 (1.3) to 16.9 (1.5)	4.3 (1.9) to 4.5 (1.9)	17.7 (1.3) to 16.9 (1.5)	93.3 (6.7) to 91.7 (4.5)
Debernardi-Venon, 1999 ²¹	11¶	Irbesartan 300 mg	8 weeks	NA	NA	18.3 (4) to 14.5 (3.4)*	NA
Schepke, 2000 ⁴⁹	14§	Irbesartan 150 mg	1 week	NA	NA	18.3 (4) to 14.7 (3.7)*	81.3 (16) to 76.7 (14.7)
	16	Placebo	1 week	NA	NA	18 (3.9) to 17.6 (3.6)	81.8 (8.6) to 87.1 (9.9)

Values are mean (SD).

NA, data not available; WHVP, wedged hepatic venous pressure; FHVP, free hepatic venous pressure; HVPG, hepatic venous pressure gradient; MAP, mean arterial pressure.

*Statistically significant.

¶One stopped due to side effects.

§Four stopped due to side effects.

C). This may be attributed to inadequate dosage to counteract the high RAAS in these patients. However, the significant changes in MAP after enalapril raise the possibility that the potential adverse effects may outweigh the potential benefits in larger doses. These opposite results for captopril compared with the enalapril studies are not easy to understand. In one study, enalapril was more effective in preventing the postural induced increase in aldosterone concentrations compared with captopril.⁴³ This may reflect more complete inhibition of ACE. Whether such differences result in different clinical effects is debatable.

ANG-II INHIBITORS

During long term ACE inhibition, alternative enzymatic pathways to ACE, such as trypsin and cathepsin, can also convert angiotensin I to ANG-II.¹⁹ This could explain why ACE inhibitors do not reduce portal pressure in cirrhotics.⁴⁴ Moreover, ACE participates in the breakdown of bradykinin to inactive peptides. Accumulation of bradykinin after ACE inhibition would worsen the systemic hyperdynamic circulation in cirrhosis and thus outweigh the beneficial effects of ACE inhibitors on portal pressure.

The development of specific antagonists of ANG-II receptors has renewed interest in the role of RAAS activation in portal hypertension and the potential benefit from its inhibition. Early in 1981, Arroyo and colleagues⁴⁵ reported that intravenous infusion of saralasin (a short acting ANG-II antagonist) induced a significant reduction in WHVP but it correlated significantly with the decrease in MAP.

Recently, Schneider and colleagues²⁰ evaluated seven days of 25 mg of the orally active ANG-II receptor antagonist losartan in 45 cirrhotics (table 4): 30 had severe (HVPG ≥20 mm Hg) and 15 moderate portal hypertension (HVPG <20 mm Hg). Losartan caused a significant ($p < 0.001$) decrease in HVPG in patients with both severe (−46.8 (15.5)%) and moderate (−44.1 (14.7)%) portal hypertension while no significant reduction was found in controls. Losartan caused a slight, albeit statistically significant, decrease in MAP in both groups of patients (−3.1 (5.0) and −3.5 (4.3) mm Hg, respectively). Liver and renal function did not deteriorate, and the authors concluded that losartan was safe and highly effective in the treatment of portal hypertension. It should be noted that only three of 45 cirrhotics had Child-Pugh grade C (25 Child A, 17 Child B). A further study

published in abstract form by Debernardi-Venon and colleagues²¹ supported the beneficial effect of ANG-II receptor antagonists in the reduction in portal pressure (table 4): 11 cirrhotics given 300 mg of irbesartan daily for two months had a significant reduction in HVPG (mean −3.7 mm Hg, −20.7%) without renal side effects. Only one patient developed symptomatic hypotension.

Irbesartan does not require hepatic metabolism to an active metabolite such as losartan and can be administered in normal dosage despite hepatic impairment.

Although the results of the study of Schneider and colleagues²⁰ appear impressive, a number of concerns have been raised.⁴⁶ Firstly, despite the mean reduction in HVPG being approximately 45% (the most effective reduction in portal pressure described for any portal hypotensive agent), there was no effect on systemic pressure. Secondly, the study was neither randomised nor blinded, and both of these methodological considerations are important to internally validate the results. Thirdly, the same dose (25 mg) of losartan in another study caused a decrease in blood pressure of 10–12 mm Hg in patients with arterial hypertension and 7–8 mm Hg in subjects with normal blood pressure.⁴⁷ Surprisingly, the MAP reduction in Schneider's study was only 3 mm Hg.²⁰ One proposed mechanism for the reduction in portal pressure by ANG-II antagonists is a decrease in portal blood flow caused by reflex splanchnic arterial vasoconstriction which in turn is caused by the reduction in blood pressure. This mode of action in cirrhotics, with an already marked peripheral vasodilatation and resultant decrease in effective blood volume, should induce further deterioration in systemic haemodynamics with deleterious effects on renal function.

However, Schneider *et al* suggested that the reduction in portal pressure with losartan was mostly due to decreased resistance of the intrahepatic vasculature without major effects on systemic haemodynamics.²⁰ However, a study using isolated perfused cirrhotic rat liver⁴⁸ showed that only 20–30% of intrahepatic resistance in cirrhosis is amenable to pharmacological manipulation and therefore only half of the average 45% reduction in portal pressure observed with losartan theoretically can be attributed to a decrease in intrahepatic resistance.

The above concerns and putative explanations for the reduction in portal pressure surfaced in the first double

blind placebo controlled study using the ANG-II antagonist irbesartan by Schepke and colleagues,⁴⁹ recently published in abstract form (table 4). Thirty cirrhotic patients with portal hypertension were randomised to receive either 150 mg of irbesartan once daily or placebo for one week. Irbesartan caused a significant reduction in HVP (mean reduction 16.7 (23)%) which was less pronounced compared with losartan.²⁰ However, in 21% of patients, treatment had to be discontinued due to arterial hypotension. Moreover, in those who completed the study there was reduced creatinine clearance.

In a further twist to this series of observations, a recently published study by Bataller and colleagues⁵⁰ showed that activated human stellate cells (HSCs) express ANG-II receptors (AT1 subtype) and that binding of ANG-II to AT1 receptors induces contraction and proliferation. The effects of ANG-II were undetectable in quiescent stellate cells, suggesting that activated stellate cells may be a target for ANG-II. Previous reports on the presence of ANG-II receptors in activated HSCs provided conflicting results¹⁶⁻⁵¹ but this could be attributed to differences in the presence or number of ANG-II receptors among species or to differences in methodology. Interestingly, in a previous study,⁵² systemic infusion of ANG-II resulted in significant cardiac and renal fibrosis but no fibrogenic response was detected in the liver. Further investigation is required to elucidate the *in vivo* effects of ANG-II in liver injury and hepatic fibrogenesis.⁵³ This effect, rather than that on portal hypertension, may be of considerable clinical relevance; for example, in patients with chronic hepatitis who would have no, or at least minimal, activation of the RAAS. If inhibition of the contractile and proliferative properties of HSCs by losartan and other ANG-II receptor antagonists is confirmed in animal models, this would open up a new therapeutic avenue in the precirrhotic patient.

Conclusion

In the study of Schneider and colleagues²⁰ which demonstrated a marked reduction in HVP with losartan and the most marked reduction in portal pressure by a drug, most patients were well compensated cirrhotics. Current data suggest that the RAAS does not have an important role in maintaining basal vascular tone in the early stages of cirrhosis³⁹ and probably not at all in chronic hepatitis. Thus administration of ANG-II inhibitors may not have a deleterious effect on systemic or renal haemodynamics in these groups of patients. Conversely, in cirrhotics with established cirrhosis or end stage liver disease, there is marked activation of the RAAS to compensate for peripheral vasodilatation and to maintain arterial pressure. In this setting, the potentially beneficial effect of ANG-II inhibitors in reducing intrahepatic resistance (via relaxation of activated stellate cells (myofibroblasts)) would be counterbalanced by their deleterious effects on systemic and renal haemodynamics.

Thus ANG-II inhibitors may turn out to be useful drugs for patients with chronic hepatitis without significant portal hypertension to postpone the development of portal hypertension, but they may also suppress stellate cell proliferation (that is, act as an antifibrotic). Further investigation along these lines may prove to be very exciting.⁵³

J VLACHOGIANNAKOS
A K W TANG
D PATCH
A K BURROUGHS

*Liver Transplantation and Hepatobiliary Medicine,
Royal Free Hospital, London, UK*

Correspondence to: Dr A K Burroughs, Liver Transplantation and Hepatobiliary Medicine, Royal Free Hospital, Pond Street, London NW3 2QG, UK. andrew.burroughs@talk21.com

- Armonis A, Patch D, Burroughs A. Hepatic venous pressure: an old test as a new prognostic marker in cirrhosis? *Hepatology* 1997;25:245-8.
- Lebrech D. Pharmacological treatment of portal hypertension: present and future. *J Hepatol* 1998;28:896-907.
- Reichen J. Liver function and pharmacological considerations in pathogenesis and treatment of portal hypertension. *Hepatology* 1990;11:1066-78.
- Vlachogiannakos J, Goulis J, Patch D, *et al.* Primary prophylaxis for portal hypertensive bleeding in cirrhosis. *Aliment Pharmacol Ther* 2000;14:851-60.
- Lebrech D, Poynard T, Bernuau J, *et al.* A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. *Hepatology* 1984;4:355-8.
- Groszmann RJ, Bosch J, Grace ND, *et al.* Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. *Gastroenterology* 1990;99:1401-7.
- Garcia-Tsao G, Grace ND, Groszmann RJ, *et al.* Short-term effects of propranolol on portal venous pressure. *Hepatology* 1986;6:101-6.
- Sims DE. The pericyte—a review. *Tissue Cell* 1986;18:153-74.
- Marra F. Hepatic stellate cells and the regulation of liver inflammation. *J Hepatol* 1999;31:1120-30.
- Rockey D. The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide. *Hepatology* 1997;25:2-5.
- Epstein M. The renin-angiotensin system in liver disease. In: Epstein M, ed. *The kidney in liver disease*. New York: Elsevier Biomedical, 1983:353-75.
- Arroyo V, Bosch J, Mauri M, *et al.* Renin, aldosterone and renal haemodynamics in cirrhosis with ascites. *Eur J Clin Invest* 1979;9:69-73.
- Garcia-Pagan JC, Bosch J, Rodes J. The role of vasoactive mediators in portal hypertension. *Semin Gastrointest Dis* 1995;6:140-7.
- Ballet F, Chretien Y, Rey C, *et al.* Differential response of normal and cirrhotic liver to vasoactive agents. A study in the isolated perfused rat liver. *J Pharmacol Exp Ther* 1988;244:233-5.
- Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. *N Engl J Med* 1996;25:1649-54.
- Pinzani M, Falli P, Ruocco C, *et al.* Fat-storing cells as liver specific pericytes. Spatial dynamics of agonist-stimulated intracellular calcium transients. *J Clin Invest* 1992;90:642-6.
- Laragh JH, Angers M, Kelly WG, *et al.* Hypotensive agents and pressor substances: the effect of epinephrine, norepinephrine, angiotensin II, and others on the secretory rate of aldosterone in man. *JAMA* 1960;174:234-40.
- Nussberger J, Waebler B, Brunner HR. Clinical pharmacology of ACE inhibition. *Cardiology* 1989;76(suppl 2):11-22.
- Burnier M, Brunner HR. Angiotensin II receptor antagonists. *Lancet* 2000;355:637-45.
- Schneider AW, Kalk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on the portal pressure in cirrhosis. *Hepatology* 1999;29:334-9.
- Debernardi-Venon W, Barletti C, Marzano A, *et al.* Efficacy of irbesartan, an angiotensin II receptor selective antagonist, in the treatment of portal hypertension. *Hepatology* 1999;30:219A.
- Ohnishi A, Ishizaki T, Murakami S, *et al.* Inpatient comparison of acute hemodynamic, hormonal, and natriuretic responses to captopril versus enalapril in liver cirrhosis. *Clin Pharmacol Ther* 1990;48:67-75.
- Pariante EA, Bataille C, Bercoff E, *et al.* Acute effect of captopril on systemic and renal haemodynamics and on renal function in cirrhotic patients with ascites. *Gastroenterology* 1985;88:1255-9.
- Daskalopoulos G, Pinzani M, Murray N, *et al.* Effect of captopril on renal function in patients with cirrhosis and ascites. *J Hepatol* 1987;4:330-6.
- Gentilini P, Romanelli RG, Villa GL, *et al.* Effect of low-dose captopril on renal haemodynamics and function in patients with cirrhosis of liver. *Gastroenterology* 1993;104:588-94.
- Girgrah N, Liu P, Collier L, *et al.* Haemodynamic, renal sodium handling, and neurohormonal effects of acute administration of low dose losartan, an angiotensin II receptor antagonist, in preascitic cirrhosis. *Gut* 2000;46:114-20.
- Saruta T, Eguchi T, Saito I. Angiotensin antagonist in liver disease. In: Epstein M, ed. *The kidney in liver disease*, 2nd edn. New York: Elsevier, 1983:441-50.
- Brunckhorst R, Wrenger E, Kühn K, *et al.* Effect of captopril therapy on sodium and water excretion in patients with liver cirrhosis and ascites. *Klin Wochenschr* 1989;67:774-83.
- Ibarra FR, Afione C, Garzon D, *et al.* Portal pressure, renal function and hormonal profile after acute and chronic captopril treatment in cirrhosis. *Eur J Clin Pharmacol* 1992;43:477-82.
- Van Vliet AA, Donker AJ, Meuwissen SG. Efficacy of low-dose captopril in addition to frusemide and spiroolactone in patients with decompensated liver disease during blunt diuresis. *J Hepatol* 1992;15:40-7.
- Wood LJ, Goergen S, Stockigt JR, *et al.* Adverse effects of captopril in treatment of resistant ascites, a state of functional bilateral renal artery stenosis. *Lancet* 1985;2:1008-9.
- Tsai YT, Lin HC, Lee FY, *et al.* Effect of captopril on renal functions, renal and portal haemodynamics in patients with cirrhosis. *Proc Natl Sci Council, Repub China B* 1996;20:44-50.
- Ohnishi A, Murakami S, Harada M, *et al.* Renal and hormonal responses to repeated treatment with enalapril in non-azotemic cirrhosis with ascites. *J Hepatol* 1994;20:223-30.
- Amarapurkar DN, Dhawan P, Kalro RH. Role of routine estimation of creatinine clearance in patients with liver cirrhosis. *Indian J Gastroenterol* 1994;13:79-82.
- Schrier RW, Arroyo V, Bernardi M, *et al.* Peripheral arterial vasodilatation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. *Hepatology* 1988;8:1151-7.
- Hall JE, Guyton AC, Jackson TE, *et al.* Control of glomerular filtration rate by renin-angiotensin system. *Am J Physiol* 1977;233:F366-72.
- Schrier RW. Renin-angiotensin in preascitic cirrhosis: Evidence for primary peripheral arterial vasodilatation. *Gastroenterology* 1998;115:489-91.
- Wong F, Sniderman K, Blendis L. The renal sympathetic and renin-angiotensin response to lower body negative pressure in well-compensated cirrhosis. *Gastroenterology* 1998;115:397-405.
- Helmy A, Jalan R, Newby DE, *et al.* Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis. *Gastroenterology* 2000;118:565-72.

- 40 Eriksson LS, Kagedal B, Wahren J. Effect of captopril on hepatic venous pressure and blood flow in patients with liver cirrhosis. *Am J Med* 1984;76:66–70.
- 41 Chiang HT, Cheng JS, Lin M, et al. Haemodynamic effect of enalaprilat on portal hypertension in patients with HBsAg-positive cirrhosis. *J Gastroenterol Hepatol* 1995;10:256–60.
- 42 Svoboda P, Ochmann J, Kantorova I. Effect of enalapril treatment and sclerotherapy of esophageal varices on hepatic haemodynamics in portal hypertension. *Hepatogastroenterology* 1992;39:549–52.
- 43 Atlas SA, Case DB, Yu ZY, et al. Hormonal and metabolic effects of angiotensin converting enzymes inhibitors. Possible differences between enalapril and captopril. *Am J Med* 1984;2077:13–17.
- 44 Johnston CJ, Clappison BH, Anderson WP, et al. Effect of angiotensin-converting enzyme inhibition on circulating and local kinins levels. *Am J Cardiol* 1982;49:1401–4.
- 45 Arroyo V, Bosch J, Maori M, et al. Effect of angiotensin II blockade on systemic and hepatic hemodynamics and on renin-angiotensin-aldosterone system in cirrhosis with ascites. *Eur J Clin Invest* 1981;11:221–9.
- 46 Garcia-Tsao G. Angiotensin II receptor antagonists in the pharmacological therapy of portal hypertension: a caution. *Gastroenterology* 1999;117:740–2.
- 47 Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. *Drugs* 1996;51:820–45.
- 48 Bhathal PS, Grossman HJ. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. *J Hepatol* 1985;1:325–37.
- 49 Schepke M, Werner E, Bicker E, et al. The angiotensin II receptor antagonist irbesartan for the treatment of portal hypertension: a placebo controlled, double-blind study. *Hepatology* 2000;32:406A.
- 50 Bataller R, Gines P, Nicolas JM, et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. *Gastroenterology* 2000;118:1149–56.
- 51 Rockey DC, Weisiger RA. Endothelin induced contractility of stellate cells from normal and cirrhotic liver: implications for regulation of portal pressure and resistance. *Hepatology* 1996;24:233–40.
- 52 Yoo KH, Thornhill BA, Wolstenholme JT, et al. Tissue-specific regulation of growth factors and clusterin by angiotensin II. *Am J Hypertens* 1998;11:715–22.
- 53 Rockey DC. Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: implications for therapy. *Gastroenterology* 2000;118:1261–5.



Have your say

eLetters

If you wish to comment on any article published in *Gut* you can send an eLetter using the eLetters link at the beginning of each article. Your response will be posted on *Gut* online within a few days of receipt (subject to editorial screening).

www.gutjnl.com